CPT 84305: Somatomedin (IGF) Assay, Serum
Commercial payers pay $52 on average nationally for this procedure.
CPT code 84305 describes a laboratory assay for somatomedin (commonly measured in serum) used to evaluate growth hormone activity; the service is a clinical laboratory endocrine test typically performed in a clinical laboratory or hospital laboratory setting on a blood specimen.
For related coverage guidance, see recent payer policy updates: Salivary Hormone Testing, Parathyroid Hormone, Phosphorus, Calcium, and Magnesium Testing, Bone Turnover Markers Testing.
Customize your policy alerts
Sign up for cpt 84305 policy alerts
Get alerted when payer policies referencing 84305 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
Commercial reimbursement for CPT 84305 clusters around the BUCA average commercial rate of $51.50, with notable variation across major payers. Blue Cross Blue Shield shows the highest central tendency (median $75.70) and a wide upper tail (P90 $122.50), while Aetna and UnitedHealth Group have much lower medians ($17.00 and $12.80 respectively). Cigna sits between those groups with a median of $19.00. These differences indicate distinct contracting positions among payers relative to the BUCA average commercial benchmark of $51.50.
Rate dispersion measured by the interquartile range (P75 minus P25) is largest for Blue Cross Blue Shield at $47.80 (P75 $97.09 minus P25 $49.20), followed by Cigna with $19.00 (P75 $30.20 minus P25 $11.70). BUCA’s interquartile spread is $35.60 (P75 $65.70 minus P25 $33.10). The tightest spread is Aetna at $6.00 (P75 $20.00 minus P25 $14.00), with UnitedHealth Group also relatively tight at $12.90 (P75 $21.30 minus P25 $9.40).